Immunomedics (NASDAQ: IMMU) and United Therapeutics Corporation (NASDAQ:UTHR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitabiliy.

Volatility and Risk

Immunomedics has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Comparatively, United Therapeutics Corporation has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.


This table compares Immunomedics and United Therapeutics Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immunomedics -3,426.56% N/A -142.88%
United Therapeutics Corporation 41.04% 34.74% 28.08%

Institutional & Insider Ownership

62.1% of Immunomedics shares are held by institutional investors. 6.6% of Immunomedics shares are held by company insiders. Comparatively, 7.8% of United Therapeutics Corporation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Immunomedics and United Therapeutics Corporation, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunomedics 0 0 3 0 3.00
United Therapeutics Corporation 3 7 2 0 1.92

Immunomedics currently has a consensus target price of $11.00, suggesting a potential upside of 21.55%. United Therapeutics Corporation has a consensus target price of $134.70, suggesting a potential upside of 3.12%. Given Immunomedics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Immunomedics is more favorable than United Therapeutics Corporation.

Valuation & Earnings

This table compares Immunomedics and United Therapeutics Corporation’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Immunomedics $3.38 million 293.47 -$63.80 million ($1.12) -8.08
United Therapeutics Corporation $1.60 billion 3.68 $993.40 million $14.21 9.19

United Therapeutics Corporation has higher revenue and earnings than Immunomedics. Immunomedics is trading at a lower price-to-earnings ratio than United Therapeutics Corporation, indicating that it is currently the more affordable of the two stocks.


United Therapeutics Corporation beats Immunomedics on 7 of the 13 factors compared between the two stocks.

Immunomedics Company Profile

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with's FREE daily email newsletter.